Ipsen, bioMérieux sign companion diagnostics pact

Ipsen and bioMérieux have created a global collaboration in theranostics with a focus on hormone-dependent cancers. The partnership emphasizes the companies' expertise in the emerging field of personalized medicine. The companies will identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors and pituitary tumors. BioMérieux got into the arena of molecular diagnostics in 2008 through the $60 million purchase of San Diego company AviaraDx. AviaraDx had developed methods of testing the molecular biology of a sample in order to diagnose cancer. Ipsen/bioMérieux release | News

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.